Supplement manufacturer NOW has partnered with a French biotechnology firm to move the needle on probiotic ingredient verification. The new initiative in conjunction with bioMérieux has spawned the development of a new PCR genetic identification technology dubbed Gene-Up Probiotic Species ID. The technology, which includes a dedicated benchtop device, enables species-level ID of probiotic strains within 90 minutes. The innovation will dramatically change the way NOW verifies its probiotics products, according to Maria Mendres, microbiology manager at NOW. “This technology significantly enhances NOW’s existing probiotic quality-control program by enabling rapid, in-house identity testing of complex, multistrain probiotic formulations. Using multiplex real-time PCR, multiple probiotic species can be detected simultaneously, allowing identity verification to be completed in approximately two hours,” she said.
This groundbreaking collaboration between NOW, a leading name in the dietary supplement industry, and bioMérieux, a global leader in in vitro diagnostics, signifies a pivotal moment in ensuring the authenticity and quality of probiotic ingredients. The newly developed Gene-Up Probiotic Species ID technology represents a significant leap forward from traditional verification methods, promising to enhance efficiency, accuracy, and reliability within the probiotic supply chain.
A New Era of Probiotic Identification: The Gene-Up Probiotic Species ID
The core of this innovation lies in the Gene-Up Probiotic Species ID technology, which leverages multiplex real-time polymerase chain reaction (PCR). This advanced molecular diagnostic technique allows for the simultaneous detection and identification of multiple probiotic species within a single sample. The system includes a dedicated, compact benchtop device, designed for ease of use within a laboratory setting.
Traditionally, verifying the identity and purity of probiotic strains has been a time-consuming and complex process. Methods often involved culturing techniques, which could take days or even weeks, and required specialized expertise. In cases where samples needed to be sent to third-party laboratories, the turnaround time could be further extended, creating bottlenecks in the production and quality control workflows.
The Gene-Up Probiotic Species ID technology drastically shortens this timeline, enabling species-level identification of probiotic strains in as little as 90 minutes. This rapid turnaround is a game-changer for manufacturers like NOW, who are committed to delivering high-quality products to consumers.
Transforming Quality Control: A Cleaner, Faster Workflow
Maria Mendres, Microbiology Manager at NOW, highlighted the profound impact of this new technology on the company’s quality control processes. "This technology significantly enhances NOW’s existing probiotic quality-control program by enabling rapid, in-house identity testing of complex, multistrain probiotic formulations," Mendres stated. "Using multiplex real-time PCR, multiple probiotic species can be detected simultaneously, allowing identity verification to be completed in approximately two hours."
The efficiency gains are substantial. By bringing this advanced testing capability in-house, NOW can significantly reduce the amount of time ingredients are held in quarantine pending positive verification. This translates to a cleaner workflow, reduced operational costs associated with extended inventory holding, and a faster time-to-market for finished products.
"Bringing multiplex real-time PCR testing in-house allows manufacturers to obtain species-level identity results much more rapidly, facilitating timely quality decisions while maintaining scientifically rigorous identity verification," Mendres explained. This speed is particularly crucial in the dynamic supplement market, where consumer demand for effective and well-characterized probiotic products is on the rise.
Addressing the Challenges of Multistrain Probiotics
The growing popularity of multistrain probiotic formulations presents unique analytical challenges. Ensuring that each specific strain is present in the correct quantity and that no contaminants have been introduced requires sophisticated testing methods. Historically, the thorough characterization of these complex mixtures could be a bottleneck, potentially leading to increased production costs or, in less scrupulous operations, incomplete quality assurance.
Mendres acknowledged this challenge, stating that the new technology could be "especially important in the years to come, as multistrain probiotics gain more traction in the marketplace. In the past, the testing of these presented a bottleneck that could potentially raise costs. Or, in the case of companies with lower ethical standards, it could have been that full characterization simply was not undertaken."
The Gene-Up Probiotic Species ID technology directly addresses this by providing a robust and accessible solution for identifying individual species within these intricate formulations. This not only ensures product integrity but also supports transparent and accurate labeling, fostering consumer trust.
Strengthening Quality Systems: Objective, DNA-Based Evidence
The implications of rapid molecular identification extend beyond mere efficiency; they fundamentally strengthen a manufacturer’s overall quality system. "Rapid molecular identification can strengthen a manufacturer’s overall quality system by providing objective, DNA-based evidence supporting the identity of probiotic microorganisms in finished products," Mendres elaborated. "This is particularly valuable for complex multistrain formulations, where confirming the presence of individual species can be analytically challenging."
The reliance on DNA-based evidence offers a level of objectivity and certainty that is difficult to achieve with traditional methods. It provides a clear, scientifically rigorous confirmation of the probiotic strains present, mitigating the risk of misidentification or adulteration.
Compared to more resource-intensive sequencing technologies, multiplex real-time PCR offers a rapid and relatively cost-effective approach. This makes robust in-house identity verification more accessible to a wider range of manufacturers, democratizing access to high-level quality control.
Industry-Wide Impact and the Evolving Probiotic Landscape
Alejo Migones, Senior VP, Global Food Safety and Quality at bioMérieux, emphasized the broader industry context and the increasing importance of reliable verification. "Probiotic manufacturers are navigating a rapidly evolving landscape where ensuring reliable species verification is becoming essential, not only for quality control, but also for minimizing operational risk, supporting accurate label claims and maintaining market access in a highly competitive category," Migones commented.
The global probiotic market has experienced significant growth, driven by increasing consumer awareness of gut health and its impact on overall well-being. Projections from various market research firms indicate a continued upward trend, with the market size expected to reach tens of billions of dollars in the coming years. This expansion necessitates robust quality control measures to maintain consumer confidence and regulatory compliance.
The partnership between NOW and bioMérieux is a proactive response to these market dynamics. By investing in advanced verification technology, they are setting a higher standard for the industry, encouraging other manufacturers to adopt similar rigorous testing protocols.
A Legacy of Testing Excellence at NOW
NOW has consistently demonstrated a commitment to quality assurance, investing in state-of-the-art in-house laboratory facilities. This dedication to testing excellence is not new; the company has previously utilized its advanced labs to conduct independent testing of supplements purchased from online marketplaces. These initiatives have frequently shed light on the prevalence of understrength products or, in some cases, products that contain none of the stated active ingredients.
This proactive approach to transparency and quality control aligns with NOW’s brand ethos and its commitment to providing consumers with reliable and effective supplements. The integration of Gene-Up Probiotic Species ID technology further solidifies this commitment, equipping the company with cutting-edge tools to uphold its stringent quality standards for probiotic products.
The Chronology of Innovation
While the specific timeline for the development and implementation of the Gene-Up Probiotic Species ID technology is not detailed in the initial announcement, such collaborations typically involve several phases:
- Research and Development: Years of research into PCR technology and its application for probiotic identification. This would have involved extensive laboratory work to develop specific primers and probes for various probiotic species.
- Partnership Formation: NOW and bioMérieux would have identified mutual interests and established a formal partnership to co-develop or license the technology for commercial use.
- Technology Development and Validation: The creation of the Gene-Up Probiotic Species ID system, including the benchtop device and the associated reagents and software. Rigorous validation studies would have been conducted to ensure accuracy, sensitivity, and specificity.
- Implementation and Training: NOW would have integrated the technology into its existing quality control workflows, requiring specialized training for its laboratory personnel.
- Ongoing Monitoring and Improvement: Continuous evaluation of the technology’s performance and potential updates or enhancements to expand its capabilities.
Supporting Data and Market Context
The probiotic market is characterized by a diverse range of products, from single-strain supplements to complex multistrain formulations targeting specific health concerns such as digestive health, immune support, and even mood regulation. The market growth is fueled by scientific research continually uncovering new benefits associated with specific probiotic strains.
For example, studies have linked certain strains of Lactobacillus and Bifidobacterium to improvements in irritable bowel syndrome (IBS) symptoms. Other research points to the potential of probiotics in supporting immune function and even influencing the gut-brain axis. This expanding scientific understanding creates a demand for accurately identified and quantified probiotic ingredients.
The cost of inadequate quality control in the supplement industry can be substantial. Beyond financial losses due to product recalls or reputational damage, there are significant health implications for consumers who may not receive the intended benefits or could be exposed to harmful contaminants. Regulatory bodies worldwide are increasingly scrutinizing the supplement industry, emphasizing the need for robust quality assurance practices.
Broader Impact and Implications for the Supplement Industry
The partnership between NOW and bioMérieux has far-reaching implications for the entire dietary supplement industry:
- Setting a New Standard: This collaboration elevates the benchmark for probiotic verification, potentially encouraging other manufacturers to invest in similar advanced technologies.
- Enhanced Consumer Trust: Increased accuracy and transparency in probiotic labeling can significantly boost consumer confidence in the efficacy and safety of these products.
- Reduced Operational Risk: Faster and more reliable testing reduces the risk of product recalls, costly investigations, and market access issues.
- Facilitating Innovation: By simplifying the verification process for complex formulations, this technology can accelerate the development and introduction of novel probiotic products.
- Combating Counterfeiting and Adulteration: Advanced genetic identification methods are powerful tools in the fight against counterfeit or adulterated ingredients, protecting both consumers and legitimate businesses.
In conclusion, the development and adoption of the Gene-Up Probiotic Species ID technology represent a significant advancement in the field of probiotic ingredient verification. This partnership between NOW and bioMérieux underscores a commitment to quality, innovation, and consumer well-being, promising to reshape how probiotic products are tested and validated in the years to come. The ability to rapidly and accurately identify probiotic strains at the species level is not merely a technical upgrade; it is a crucial step towards ensuring the integrity and efficacy of these increasingly popular health-supporting supplements.
